Study of elranatamab after initial treatment for plasmablastic lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an investigational drug called elranatamab to see if it can help keep plasmablastic lymphoma from coming back after you've finished your first treatment. The drug targets a protein on the cancer cells to help your immune system fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with plasmablastic lymphoma (a rare and aggressive type of lymphoma).
- You finished your first round of treatment and your disease responded (either partial or complete response).
- Your blood counts, kidney, and liver function are adequate, and you have recovered from the side effects of prior treatment.
- You are willing to provide a tissue sample from your tumor for testing.
- If you are HIV-positive, you must be on effective HIV medication and have a CD4 count of at least 50.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
This trial tests a new targeted medicine called elranatamab for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs. It aims to see if this treatment can help control the disease.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a new drug, elranatamab, for people with multiple myeloma who recently received a CAR-T cell therapy (cilta-cel) but still have high-risk features. The goal is to see if elranatamab can help keep the cancer from coming back.
Hear when a new Plasmablastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.